LncRNA XLOC_003810 promotes T cell activation and inhibits PD-1/PD-L1 expression in patients with myasthenia gravis-related thymoma
- 1 July 2020
- journal article
- research article
- Published by Wiley in Scandinavian Journal of Immunology
- Vol. 92 (1), e12886
- https://doi.org/10.1111/sji.12886
Abstract
This study aimed to investigate the effect of long non-coding RNA XLOC_003810 on the activation of CD4(+) T cells and expression of PD-1/PD-L1 in patients with myasthenia gravis-related thymoma (MG-T). Thymus specimens and thymic mononuclear cells were obtained from MG and MG-T patients or cardiac surgery patients undergoing thoracotomy who were selected as negative controls (NC). XLOC_003810 expression was examined using quantitative real-time PCR (qRT-PCR). Frequency of CD4(+) T cells and proportion of CD4(+)PD-1(+) T cells and CD14(+)PD-L1(+) monocytes were quantified by flow cytometry. The release of inflammatory cytokines was measured by qRT-PCR and enzyme-linked immunosorbent assay. Compared with the NC group, expression of XLOC_003810, frequency of CD4(+) T cells and the production of inflammatory cytokines were increased in patients with MG and MG-T. XLOC_003810 overexpression significantly increased the frequency of CD4(+) T cells, facilitated the production of inflammatory cytokines and decreased the proportion of CD4(+)PD-1(+) T cells and CD14(+)PD-L1(+) monocytes in the thymic mononuclear cells. In contrast, XLOC_003810 knockdown exerted the opposite effect. Together, XLOC_003810 promotes T cell activation and inhibits PD-1/PD-L1 pathway in patients with MG-T.Keywords
Funding Information
- Natural Science Foundation of Anhui Province (1808085QH245)
This publication has 26 references indexed in Scilit:
- Altered expression of miR-125a-5p in thymoma-associated myasthenia gravis and its down-regulation of foxp3 expression in Jurkat cellsImmunology Letters, 2016
- Autoreactive T Cells from Patients with Myasthenia Gravis Are Characterized by Elevated IL-17, IFN-γ, and GM-CSF and Diminished IL-10 ProductionPublished by The American Association of Immunologists ,2016
- Aberrant decrease of microRNA19b regulates TSLP expression and contributes to Th17 cells development in myasthenia gravis related thymomasJournal of Neuroimmunology, 2015
- IL‐17‐producing CD4+ T cells contribute to the loss of B‐cell tolerance in experimental autoimmune myasthenia gravisEuropean Journal of Immunology, 2015
- The PD-1/PD-L1 pathway: biological background and clinical relevance of an emerging treatment target in immunotherapyEmerging Therapeutic Targets, 2014
- Myasthenia gravis: A comprehensive review of immune dysregulation and etiological mechanismsJournal of Autoimmunity, 2014
- The thymus in autoimmune Myasthenia Gravis: Paradigm for a tertiary lymphoid organRevue Neurologique, 2013
- Aberrant production of soluble inducible T-cell co-stimulator (sICOS) and soluble programmed cell death protein 1 (sPD-1) in patients with chronic hepatitis CMolecular Medicine Reports, 2013
- Programmed Death-1: From gene to protein in autoimmune human myasthenia gravisJournal of Neuroimmunology, 2007
- Selective loss of regulatory T cells in thymomasAnnals of Neurology, 2004